PDF(Pubmed)
Abstract：
HMG-CoA reductase inhibitors, commonly known as statins, are the primary treatment choice for cardiovascular diseases, which stand as the leading global cause of mortality. Statins also offer various pleiotropic effects, including improved endothelial function, anti-inflammatory properties, reduced oxidative stress, anti-thrombotic effects, and the stabilization of atherosclerotic plaques. However, the usage of statins can be accompanied by a range of adverse effects, such as the development of type 2 diabetes mellitus, muscular symptoms, liver toxicity, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric complications. These issues are referred to as statin-associated symptoms (SAS) and are relatively infrequent in clinical trials, making it challenging to attribute them to statin use definitively. Therefore, these symptoms can lead to significant problems, necessitating dose adjustments or discontinuation of statin therapy. This review aims to provide a comprehensive overview of the mechanism of action, potential advantages, and associated risks of statin utilization in clinical settings.
摘要：
HMG-CoA还原酶抑制剂，通常被称为他汀类药物，是心血管疾病的主要治疗选择，这是全球主要的死亡原因。他汀类药物还提供各种多效作用，包括改善内皮功能，抗炎特性，减少氧化应激，抗血栓作用,和动脉粥样硬化斑块的稳定。然而,他汀类药物的使用可能伴随着一系列的不良反应，例如2型糖尿病的发展，肌肉症状,肝毒性,肾脏疾病，白内障,出血性中风,和精神并发症。这些问题被称为他汀类药物相关症状（SAS），在临床试验中相对罕见。这使得将它们归因于他汀类药物的使用成为挑战。因此,这些症状会导致严重的问题，需要调整剂量或停止他汀类药物治疗。这篇综述旨在全面概述行动机制,潜在优势,以及在临床环境中使用他汀类药物的相关风险。
